Hutchison China MediTech Ltd – (NASDAQ:HCM) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price objective of $41.00 for the company, according to Zacks. Zacks has also assigned Hutchison China MediTech an industry rank of 178 out of 265 based on the ratings given to related companies.
Several analysts have commented on the company. BidaskClub upgraded Hutchison China MediTech from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Canaccord Genuity increased their target price on Hutchison China MediTech to $38.00 and gave the company a “buy” rating in a research note on Monday, October 16th.
A number of institutional investors and hedge funds have recently modified their holdings of HCM. Harvest Fund Management Co. Ltd purchased a new position in shares of Hutchison China MediTech in the 4th quarter worth $10,334,000. JPMorgan Chase & Co. purchased a new position in shares of Hutchison China MediTech in the 2nd quarter worth $5,102,000. Schroder Investment Management Group boosted its stake in shares of Hutchison China MediTech by 2.1% in the 3rd quarter. Schroder Investment Management Group now owns 997,164 shares of the company’s stock worth $27,163,000 after buying an additional 20,800 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Hutchison China MediTech by 10.8% in the 3rd quarter. Baillie Gifford & Co. now owns 185,604 shares of the company’s stock worth $5,062,000 after buying an additional 18,057 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Hutchison China MediTech in the 3rd quarter worth $273,000. Institutional investors and hedge funds own 3.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/29/zacks-analysts-set-41-00-price-target-for-hutchison-china-meditech-ltd-hcm.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.